摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(5R)-3-(4-(1,2,5,6-tetrahydropyridin-4-yl)-3,5-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)-oxazolidin-2-one hydrochloride | 371194-79-5

中文名称
——
中文别名
——
英文名称
(5R)-3-(4-(1,2,5,6-tetrahydropyridin-4-yl)-3,5-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)-oxazolidin-2-one hydrochloride
英文别名
(5R)-3-[3,5-difluoro-4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]-5-(1,2,4-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;hydrochloride
(5R)-3-(4-(1,2,5,6-tetrahydropyridin-4-yl)-3,5-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)-oxazolidin-2-one hydrochloride化学式
CAS
371194-79-5
化学式
C17H17F2N5O2*ClH
mdl
——
分子量
397.812
InChiKey
RHIDNEXQCIFNOL-ZOWNYOTGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.38
  • 重原子数:
    27
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    72.3
  • 氢给体数:
    2
  • 氢受体数:
    7

文献信息

  • Oxazolidinone derivatives with antibiotic activity
    申请人:——
    公开号:US20030216373A1
    公开(公告)日:2003-11-20
    Compounds of the formula (I), or a pharmaceutically acceptable salt, or an in-vivo-hydrolysable ester thereof, 1 wherein HET is an N-linked 5-membered heteroaryl ring, optionally substituted on a C atom by an oxo or thioxo group; and/or by 1 or 2 (1-4C)alkyl groups; and/or on an available nitrogen atom by (1-4C)alkyl; or HET is an N-linked 6-membered heteroaryl ring containing up to three nitrogen heteroatoms in total, optionally substituted on a C atom as above; Q is selected from, for example, Q1 2 R 2 and R 3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, of formula (TC 5 ) 3 wherein Rc is, for example, R 13 CO—, R 13 SO 2 — or R 13 CS—; wherein R 13 is, for example, optionally substituted (1-10C)alkyl or R 14 C(O)O(1-6C)alkyl wherein R 14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.
    公式(I)的化合物,或其药学上可接受的盐,或其体内解酯,其中HET是一个N-连接的5-成员杂环芳基环,可选地在碳原子上被氧化或代氧基取代;和/或由1或2个(1-4C)烷基基团取代;和/或在一个可用的氮原子上由(1-4C)烷基基团取代;或者HET是一个N-连接的6-成员杂环芳基环,总共包含最多三个氮杂原子,可选地在碳原子上如上所述取代;Q是选自,例如,Q12R2和R3独立地是氢或;T是选自一系列基团,例如,如下式(TC5)3其中Rc是,例如,R13CO—,R13SO2—或R13CS—;其中R13是,例如,可选地取代的(1-10C)烷基或R14C(O)O(1-6C)烷基,其中R14是可选地取代的(1-10C)烷基;作为抗菌剂是有用的;并描述了它们的制备方法和含有它们的药物组合物。
  • [EN] OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY<br/>[FR] DERIVES D'OXAZOLIDINONE AYANT UNE ACTIVITE ANTIBIOTIQUE
    申请人:ASTRAZENECA AB
    公开号:WO2001081350A1
    公开(公告)日:2001-11-01
    Compounds of formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein HET is an N-linked 5-membered heteroaryl ring, optionally substituted on a C atom by an oxo or thioxo group; and/or by 1 or 2(1-4C) alkyl groups; and/or on an available nitrogen atom by (1-4C)alkyl; or HET is an N-linked 6-membered heteroaryl ring containing up to three nitrogen heteroatoms in total, optionally substituted on a C atom as above; Q is selected from, for example, (Q1), R?2 and R3¿ are independently hydrogen or fluoro; T is selected from a range of groups, for example, of formula (TC5), wherein Rc is, for example, R?13CO-, R13SO¿2- or R13CS-; wherein R13 is, for example, optionally substituted (1-10C)alkyl or R14C(O)O(1-6C)alkyl wherein R14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.
    公式(I)的化合物,或其药学上可接受的盐,或其体内可解的酯,其中HET是N-连接的5成员杂芳环,可选择在C原子上由氧或代氧基取代; 和/或由1或2(1-4C)烷基取代; 和/或在可用的氮原子上由(1-4C)烷基取代; 或者HET是N-连接的6成员杂芳环,总共包含最多三个氮杂原子,可选择在C原子上如上所述取代; Q是从(Q1)中选择,R?2和R3¿独立地为氢或; T是从一系列基团中选择,例如公式(TC5),其中Rc是例如R?13CO-,R13SO¿2-或R13CS-;其中R13例如是可选择取代的(1-10C)烷基或R14C(O)O(1-6C)烷基,其中R14是可选择取代的(1-10C)烷基; 适用于抗菌剂; 并描述了其制造过程和含有它们的制药组合物。
  • OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY
    申请人:AstraZeneca AB
    公开号:EP1286998B1
    公开(公告)日:2004-06-09
  • US7141583B2
    申请人:——
    公开号:US7141583B2
    公开(公告)日:2006-11-28
查看更多